PMA P220013S028

Device
TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ (A-TFDM-D, A-TFDM-F, A-TFDM-J, A-TFDM-DD, A-TFDM-DF, A-TFDM-FF, A-TFDM
Applicant
ABBOTT MEDICAL
PMA number
P220013
Supplement
S028
Decision date
2026-09-04
Classification
Cardiovascular
Approval order statement
The TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ is indicated for use in The TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ is indicated for use in cardiac electrophysiological mapping and ablation for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation and concomitant atrial flutter, when used in conjunction with a compatible radiofrequency (RF) or pulsed field (PF) generator and three-dimensional mapping system.

Current openFDA PMA Record#

Device
TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ (A-TFDM-D, A-TFDM-F, A-TFDM-J, A-TFDM-DD, A-TFDM-DF, A-TFDM-FF, A-TFDM
Applicant
ABBOTT MEDICAL
PMA number
P220013
Supplement
S028
Decision date
2026-09-04
Decision code
APPR
Date received
2026-03-02
Supplement type
Panel Track
Supplement reason
Change Design/Components/Specifications/Material
Approval order statement
The TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ is indicated for use in The TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ is indicated for use in cardiac electrophysiological mapping and ablation for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation and concomitant atrial flutter, when used in conjunction with a compatible radiofrequency (RF) or pulsed field (PF) generator and three-dimensional mapping system.